Sunitinib resistance in renal cell carcinoma
<p>Of the many targeted therapies introduced since 2006, sunitinib has carved its way to become the most commonly used first-line therapy for the treatment of metastatic renal cell carcinoma (RCC). Despite significant improvements in progression-free survival, 30% of the patients are intrinsic...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Codon Publications
2014-04-01
|
| Series: | Journal of Kidney Cancer and VHL |
| Subjects: | |
| Online Access: | http://jkcvhl.com/index.php/jkcvhl/article/view/7 |
| _version_ | 1819029563221475328 |
|---|---|
| author | Christudas Morais |
| author_facet | Christudas Morais |
| author_sort | Christudas Morais |
| collection | DOAJ |
| description | <p>Of the many targeted therapies introduced since 2006, sunitinib has carved its way to become the most commonly used first-line therapy for the treatment of metastatic renal cell carcinoma (RCC). Despite significant improvements in progression-free survival, 30% of the patients are intrinsically resistant to sunitinib and the remaining 70% who respond initially will eventually become resistant in 6–15 months. While the molecular mechanisms of acquired resistance to sunitinib have been unravelling at a rapid rate, the mechanisms of intrinsic resistance remain elusive. Combination therapy, sunitinib-rechallenge and sequential therapy have been investigated as means to overcome resistance to sunitinib. Of these, sequential therapy appears to be the most promising strategy. This mini review summarises our emerging understanding of the molecular mechanisms, and the strategies employed to overcome sunitinib resistance.</p> |
| first_indexed | 2024-12-21T06:16:15Z |
| format | Article |
| id | doaj.art-dd813154bf614fc493704b48f9697642 |
| institution | Directory Open Access Journal |
| issn | 2203-5826 |
| language | English |
| last_indexed | 2024-12-21T06:16:15Z |
| publishDate | 2014-04-01 |
| publisher | Codon Publications |
| record_format | Article |
| series | Journal of Kidney Cancer and VHL |
| spelling | doaj.art-dd813154bf614fc493704b48f96976422022-12-21T19:13:24ZengCodon PublicationsJournal of Kidney Cancer and VHL2203-58262014-04-011111110.15586/jkcvhl.2014.71Sunitinib resistance in renal cell carcinomaChristudas Morais0Centre for Kidney Disease Research, School of Medicine, University of Queensland<p>Of the many targeted therapies introduced since 2006, sunitinib has carved its way to become the most commonly used first-line therapy for the treatment of metastatic renal cell carcinoma (RCC). Despite significant improvements in progression-free survival, 30% of the patients are intrinsically resistant to sunitinib and the remaining 70% who respond initially will eventually become resistant in 6–15 months. While the molecular mechanisms of acquired resistance to sunitinib have been unravelling at a rapid rate, the mechanisms of intrinsic resistance remain elusive. Combination therapy, sunitinib-rechallenge and sequential therapy have been investigated as means to overcome resistance to sunitinib. Of these, sequential therapy appears to be the most promising strategy. This mini review summarises our emerging understanding of the molecular mechanisms, and the strategies employed to overcome sunitinib resistance.</p>http://jkcvhl.com/index.php/jkcvhl/article/view/7renal cell carcinomasunitinibresistancekidney cancer |
| spellingShingle | Christudas Morais Sunitinib resistance in renal cell carcinoma Journal of Kidney Cancer and VHL renal cell carcinoma sunitinib resistance kidney cancer |
| title | Sunitinib resistance in renal cell carcinoma |
| title_full | Sunitinib resistance in renal cell carcinoma |
| title_fullStr | Sunitinib resistance in renal cell carcinoma |
| title_full_unstemmed | Sunitinib resistance in renal cell carcinoma |
| title_short | Sunitinib resistance in renal cell carcinoma |
| title_sort | sunitinib resistance in renal cell carcinoma |
| topic | renal cell carcinoma sunitinib resistance kidney cancer |
| url | http://jkcvhl.com/index.php/jkcvhl/article/view/7 |
| work_keys_str_mv | AT christudasmorais sunitinibresistanceinrenalcellcarcinoma |